anti-VEGF agentbiological drugsnanoparticlesocular neovascularizationCurrently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti￢EGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and ...
We thank Genentech for kindly providing the G6-31 anti-VEGF antibody; Dr. Wen-Rong Lie from EMD Millipore for the mouse angiogenesis/growth factor magnetic bead panel kit; Lily Morikawa and Napoleon Law from the Pathology Core Centre of the Modeling Human Disease Toronto Centre for Phenogenomics...
Anti-vascular endothelial growth factor (VEGF) therapy, including bevacizumab, is therefore a major option in targeting angiogenesis, especially for the management of stage-IV nonsmall cell lung cancer patients. This review focuses first on the data from phase-III clinical trials available to date ...
In addition, chronic anti-angiogenic therapy with bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, with enhanced hypoxia produced responses similar to these CYLD-regulated proinflammatory responses in a xenograft mouse model. Histologically, CYLD clearly prevented massive immune cell...
Antiangiogenic treatment targeting the vascular endothelial growth factor (VEGF) pathway is a powerful tool to combat tumor growth and progression; however, drug resistance frequently emerges. We identify CD5L (CD5 antigen-like precursor) as an important
Bevacizumab (Avastin, Genentech) is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), a critical angiogenic factor involved in both physiological and pathological conditions. It has been recently approved by the US FDA as a first-line therapy for widespread metastatic ...
We studied the biological activity of anti-VEGF antibodies in patients' blood during anti- VEGF therapy by using the Ba/F3-VEGFR2 cell line, which is dependent on VEGF for its growth. Methods: Serum samples from 22 patients with cancer before and during treatment with bevacizumab were tested ...
- 《Rheumatology & Therapy》 被引量: 0发表: 2021年 3PC-024 The effects of freeze–thaw cycling on the stability of the adalimumab biosimilar SB5 Aim and objectives To evaluate the stability of SB5 prefilled syringes (PFS) following short term exposure to high and low temperature conditions....
Anti-VEGF therapy leads to various glomerular injuries, including MCN/FSG- and TMA-like syndromes. In our group of patients, we show for the first time that MCN/FSG lesions, which are mostly observed following RTKI therapy, are associated with a high abundance of c-mip. In contrast, in ...
The number of patients in need of treatment is expected to dramatically increase in the coming years due to new indications for anti-VEGF therapy and an aging population5. Although the intravitreal route of administration is considered to be safe, there is also an inevitable risk of surgical ...